Monographie - Epirubicin hydrochloride

Pēdējā atjaunošana :
08/05/2024

Epirubicin hydrochloride

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Anthracine	Malaizija
Axirubicine	Vācija
Bendaepi	Vācija
Binarin	Meksika
Bioepycina	Polija
Crisabon	Argentīna
Cuatroepi	Argentīna
Ecclepia	Rumānija
Elebicin	Meksika
Ellence	Amerikas Savienotās Valstis
Epi Cell	Vācija
Epidoxo	Argentīna, Čīle, Venecuēla
Epifil	Ekvadora
Epilem	Kolumbija, Meksika
Epimedac	Vācija
Epirubicin	Austrālija, Austrija, Beļģija, Dānija, Islande, Jaunzēlande, Lielbritānija, Saūda Arābija, Šveice, Turcija, Ungārija, Zviedrija
Epirubicina	Argentīna, Ekvadora, Kolumbija, Meksika, Rumānija, Spānija
Epirubicine	Beļģija, Francija, Šveice
Farmarubicin	Turcija
Farmorubicin	Austrija, Brazīlija, Dānija, Grieķija, Norvēģija, Saūda Arābija, Somija, Šveice, Zviedrija
Farmorubicin CSV	Dienvidāfrikas Republika
Farmorubicin PFS	Horvātija, Polija, Slovēnija
Farmorubicin RD	Brazīlija, Krievu, Polija, Šveice
Farmorubicin RTU	Holande
Farmorubicina	Brazīlija, Itālija, Portugāle, Spānija
Farmorubicine	Beļģija, Francija
Pharmorubicin	Lielbritānija

Literatūras saraksts : Epirubicin hydrochloride

	Tips	Publicēšana
148	Žurnāls	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Žurnāls	De Vroe C, De Muynck C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Žurnāls	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Žurnāls	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
887	Žurnāls	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Žurnāls	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Žurnāls	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Žurnāls	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Žurnāls	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Žurnāls	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Žurnāls	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Žurnāls	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Žurnāls	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Laboratorija	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Žurnāls	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Laboratorija	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Laboratorija	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Žurnāls	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	Plakāts	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Žurnāls	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.
4352	Žurnāls	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.

Mentions Légales